NorthWest Biotherapeutics Inc (NWBO)

[Hopeforthefuture3]

Gary, read the full journal article- it is not that complex. It has good information and really is the same facts as presented at NYAS in May only now fully peer reviewed.
Imo there is more information to be shared hopefully in additional papers and or presentations.
I would like to see the outcomes on the other secondary endpoints as shown for the SAP on the European sites. Would like to see additional details on the placebo group both for those that crossed over and those that never got dcvax.
In some of dr Liau's earlier presentations she talked about genetic subtypes and that they planned to do this analysis for the trial patients - I wonder if most of the 5 year survivors were mesenchymal group. I believe there is much yet to learn from the trial data beyond the paper and hope they will share it. For now at least the quiet period should at last be over